Table 4

Adjusted relationship between HbA1c and sedentary time by bout-length categories (mean hours/day), BMI, age and use of antidiabetic drugs in patients with or without DM

	All patients (n=338)			No DM (n=270)			DM (n=68)
	β	CI	Pvalue	β	CI	P value	β	CI	P value
Bout-length category (min)
<30	0.02	−0.08 to 0.12	0.725	−0.08	−0.25 to 0.08	0.311	0.24	−0.03 to 0.50	0.052
30–59	0.01	−0.06 to 0.09	0.734	0.01	−0.13 to 0.12	0.910	0.06	−0.15 to 0.27	0.292
60–89	0.04	−0.05 to 0.13	0.363	0.01	−0.15 to 0.13	0.899	0.16	−0.05 to 0.38	0.214
≥90	0.04	−0.05 to 0.13	0.417	−0.12	−0.27 to 0.02	0.105	0.43	0.17 to 0.72	0.008
BMI	0.06	0.02 to 0.14	0.127	0.20	0.08 to 0.33	0.001	−0.2	−0.37 to 0.04	0.202
Age	0.05	−0.03 to 013	0.198	0.20	0.07 to 0.33	0.002	−0.1	−0.28 to 0.15	0.978
Antidiabetic drugs	0.71	0.48 to 0.93	<0.001	–	–	–	0.4	−0.04 to 0.84	<0.001

BMI=weight/height².
Antidiabetic drugs are defined as Anatomical Therapeutic Chemical A10.
BMI, body mass index; DM, diabetes mellitus; HbA1C, glycated haemoglobin.